Urology
Volume 57, Issue 4, Supplement 1 , Pages 64-67 , April 2001

Androgen antagonists: Potential role in prostate cancer prevention

  • Donald L Trump

      Affiliations

    • University of Pittsburgh, Pittsburgh, Pennsylvania, USA (DLT)
    • Corresponding Author InformationReprint requests: Donald L. Trump, MD, Department of Medicine and Urology, University of Pittsburgh, 200 Lothrop Street, N 723 MUH, Pittsburgh, PA 15213
    • ,
  • Joanne A Waldstreicher

      Affiliations

    • Merck & Co., Rahway, New Jersey, USA (JAW)
    • Dr. Waldstreicher holds stock in Merck & Co., Inc. Dr. Kolvenbag holds stock in AstraZeneca. Dr. Neubauer holds stock in Eli Lilly & Company and is a patent inventor of some of the reagents described herein.
    • ,
  • Geert Kolvenbag

      Affiliations

    • AstraZeneca, Wilmington, Delaware, USA (GK)
    • Dr. Waldstreicher holds stock in Merck & Co., Inc. Dr. Kolvenbag holds stock in AstraZeneca. Dr. Neubauer holds stock in Eli Lilly & Company and is a patent inventor of some of the reagents described herein.
    • ,
  • Paul S Wissel

      Affiliations

    • Glaxo Wellcome Inc., Research Triangle Park, North Carolina, USA (PSW)
    • ,
  • Blake L Neubauer

      Affiliations

    • Eli Lilly and Company, Indianapolis, Indiana, USA (BLN)

References 

  1. Huggins C, Hodges CV. Studies in prostatic cancer (I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate). Cancer Res. 1941;1:293–297
  2. Medical Research Council Prostate Cancer Working Party Investigative Group . Immediate versus deferred treatment for advanced prostatic cancer (initial results of the Medical Research Council Trial). Br J Urol. 1997;79:235–246
  3. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  4. Messing EM, Manoloa J, Sarosdy M, et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  5. Fisher B, Costantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer (report of the National Surgical Adjuvant Breast and Bowel Project P-1 study). J Natl Cancer Inst. 1998;90:1371–1388
  6. Leuprolide Study Group . Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med. 1984;311:1281–1286
  7. Byar DP. Proceedings (The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate). Cancer. 1973;32:1126–1130
  8. Daniell HW, Dunn SR, Ferguson DW, et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181–186
  9. Quella SK, Loprinzi CL, Sloan J. Pilot evaluation of venlafaxine for the treatment of hot flashes in men under androgen ablation therapy for prostate cancer. J Urol. 1999;162:98–102
  10. Feigl P, Blumenstein B, Thompson I, et al.  Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 1995;16:150–163
  11. Gormley GJ, Stoner E, Bruskewitz RC, et al.  The effect of finasteride in men with benign prostatic hyperplasia (the final group). N Engl J Med. 1992;327:1185–1191
  12. Andriole G, Lieber M, Smith J, et al.  Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995;45:491–497
  13. Span PN, Voller MC, Smals AG, et al.  Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase enzymatic activity in the human prostate. J Urol. 1999;161:332–337
  14. McNulty AM, Bemis KG, Audia JE, et al.  Kinetic analysis of LY320236 (competitive inhibitor of human type I and non-competitive inhibitor of human type II steroid 5 alpha reductase). J Steroid Biochem Mol Biol. 2000;72:13–21
  15. Reichardt JK, Makridakis N, Henderson BE, et al.  Genetic variability of the human SRD5A2 gene (implications for prostate cancer). Cancer Res. 1995;55:3973–3975
  16. Sarosdy MF, Schellhammer PF, Johnson R, et al.  Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?. Urology. 2000;55:391–395
  17. Chodak G, Sharifi R, Kasimis B, et al.  Single-agent therapy with bicalutamide (a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma). Urology. 1995;46:849–855
  18. Decensi AU, Boccardo F, Guarneri D, et al.  Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate (The Italian Prostatic Cancer Project). J Urol. 1991;146:377–381
  19. Boccardo F, Rubagotti A, Barichello M, et al.  Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients (results of an Italian Prostate Cancer Project study). J Clin Oncol. 1999;17:2027–2038
  20. Tyrrell CJ, Kaisary AV, Iversen P, et al.  A randomized comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447–456
  21. Iversen P, Tyrrell CJ, Kaisary AV, et al.  Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer (results from multicenter randomized trials at a median follow-up of 4 years). Urology. 1998;51:389–396
  22. Iversen P, Tveter K, Varenhorst E. Randomized study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer (The Scandinavian Casodex Cooperative Group). Scand J Urol Nephrol. 1996;30:93–98

PII: S0090-4295(00)00943-2

Urology
Volume 57, Issue 4, Supplement 1 , Pages 64-67 , April 2001

Article Tools